These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11698916)

  • 21. [Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha].
    Pottier P; Planchon B; Grossi O
    Rev Med Interne; 2003 Aug; 24(8):542-6. PubMed ID: 12888176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The hypereosinophilic syndrome: case report].
    Mikołajczyk K; Zaba R; Walkowiak B; Grzybowski G; Samborski W
    Ann Acad Med Stetin; 2006; 52 Suppl 2():65-9. PubMed ID: 17471838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.
    Choi IK; Kim BS; Lee KA; Ryu S; Seo HY; Sul H; Choi JG; Sung HJ; Park KH; Yoon SY; Oh SC; Seo JH; Choi CW; Shin SW; Yoon SY; Cho Y; Kim YK; Kim YH; Kim JS
    Am J Hematol; 2004 Dec; 77(4):366-9. PubMed ID: 15551277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CML clonal evolution with resistance to single agent imatinib therapy.
    Swords R; Quinn J; Fay M; O'Donnell R; Goldman J; Murphy PT
    Clin Lab Haematol; 2005 Oct; 27(5):347-9. PubMed ID: 16178920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
    Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
    Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
    [No Abstract]   [Full Text] [Related]  

  • 26. Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission.
    Cervetti G; Galimberti S; Carulli G; Petrini M
    Leuk Res; 2005 Sep; 29(9):1097-8. PubMed ID: 16038739
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases].
    Coutant G; Blétry O; Prin L; Hauteville D; de Puyfontaine O; Abgrall JF; Godeau P
    Ann Med Interne (Paris); 1993; 144(4):243-50. PubMed ID: 8368716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.
    Ghanima W; Kahrs J; Dahl TG; Tjonnfjord GE
    Eur J Haematol; 2004 Jun; 72(6):441-3. PubMed ID: 15128424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib-responsive hypereosinophilia in a patient with B cell ALL.
    Robyn J; Noel P; Wlodarska I; Choksi M; O'neal P; Arthur D; Dunbar C; Nutman T; Klion A
    Leuk Lymphoma; 2004 Dec; 45(12):2497-501. PubMed ID: 15621767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
    Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
    Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate.
    Christoforidou A; Kotsianidis I; Margaritis D; Anastasiadis A; Douvali E; Tsatalas C
    Am J Hematol; 2012 Jan; 87(1):131-2. PubMed ID: 21919038
    [No Abstract]   [Full Text] [Related]  

  • 33. Mucosal ulcerations revealing primitive hypereosinophilic syndrome.
    Barouky R; Bencharif L; Badet F; Salles G; Vital Durand D; Rousset H
    Eur J Dermatol; 2003; 13(2):207-8. PubMed ID: 12695143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Alpha interferon treatment in idiopathic hypereosinophilic syndrome resistant to conventional therapy].
    Esteve J; Cervantes F; Bosch F; Cobo F; Montserrat E; Rozman C
    Med Clin (Barc); 1996 Mar; 106(8):304-6. PubMed ID: 8667689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction.
    Onitilo AA; Kio EA; Singh AK; Lazarchick J
    Leuk Lymphoma; 2005 Nov; 46(11):1667-70. PubMed ID: 16236620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses.
    Smith KJ; Jacobson E; Hamza S; Skelton H
    Arch Dermatol; 2004 May; 140(5):584-8. PubMed ID: 15148104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The hypereosinophilic syndromes: still more heterogeneity.
    Gleich GJ; Leiferman KM
    Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of hypereosinophilic syndromes--the first 100 years.
    Butterfield JH; Weiler CR
    Semin Hematol; 2012 Apr; 49(2):182-91. PubMed ID: 22449628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.